Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. Central Nervous System
  4. Back
  5. Conditions and Management
  6. Sativex® (use of) in Spasticity due to Multiple Sclerosis (1083)
Please update your RDS mobile app to version 4.7.1

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits. 

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number.  To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

Sativex® (use of) in Spasticity due to Multiple Sclerosis (1083)

A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments.

Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty.

If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient.

Resources

Use the button below to access this item.

Access this resource

Editorial Information

Last reviewed: 24/05/2023

Next review date: 28/02/2025

Author(s): Teng Cheng Khoo.

Version: 1

Author email(s): tengcheng.khoo3@nhs.scot.

Approved By: Regional Services Clinical Governance Group

Reviewer name(s): Teng Cheng Khoo.

Document Id: 1083

Related resources

1. Sativex® oromucosal Spray Summary of Product Characteristics (last updated on eMC 24 Aug 2018). Available from https://www.medicines.org.uk/emc/product/602
2. RCP Guideline: Spasticity in adults management using botulinum toxin, 2018. Available from: http://www.rcplondon.ac.uk/guidelines-policy/spasticity-adults-management-using-botulinum-toxin
3. NICE Clinical Guideline 144: Cannabis-based medicinal products, November 2019. Available from: https://www.nice.org.uk/guidance/ng144
4. NICE Clinical Guideline 220: Multiple sclerosis in adults: management, June 2022. Available from: http://https://www.nice.org.uk/guidance/ng220